pharmaceuticals - Publications - Faculty & Research

February 26, 2003
Article

Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising

By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman

Keywords: Customers; Advertising; Health; Pharmaceutical Industry

Citation

Find at Harvard

Read Now

Profile

Evan Rachlin

experienced as a medical student, business issues are an inescapable reality for any physician. While shadowing a pediatrician in private practice, he noticed the tension between the busy physician and a pharmaceutical representative... View Details

01 Dec 2003
News

Alumni Luminaries Discuss Careers, Values with HBS Students

Internal Revenue Service. Senior advisor, The Carlyle Group. He upgraded technology and information systems and stressed customer service in a dramatic turnaround of the IRS. Daniel L. Vasella, M.D. (PMD 57, 1989), chairman and CEO of Novartis AG, the world’s... View Details

01 Mar 2009
News

A New Approach to Health-Care Reform

approach not just to insurance and reimbursement, but also to the places where medical services are delivered, the way we use technology, the way pharmaceuticals are developed, the way we educate medical professionals, and who performs... View Details

Keywords: Deborah Blagg; Health, Social Assistance

Student-Profile

Olivia Zhao

pros and cons of a public system facing increased privatization. Research Olivia’s research hones in on the pharmaceutical industry and looking at the lifecycle of a drug. “It starts, of course, with research and development at huge drug... View Details

01 Jan 2004
News

Donald P. Nielsen, MBA 1963

self-cleaning rat cages for psychology labs. Learning that pharmaceutical companies use large quantities of rats, they negotiated a deal with him and over the next few months also executed a roll-up strategy that eventually made them the... View Details

13 Jan 2003
Research & Ideas

Making Biotech Work as a Business

influenced the industry by proving that intellectual property could be monetized through alliances with big pharmaceutical partners, according to Pisano. Genentech cut its first deal with Eli Lilly in 1982 and new entrants were excited.... View Details

Keywords: by Martha Lagace; Biotechnology; Health; Technology

November 1969 (Revised February 1973)
Background Note

Note on the U.S. Prescription Drug Industry, Part II

By: Hugo Uyterhoeven and Audrey T. Sproat

Keywords: Pharmaceutical Industry; United States

Citation

Find at Harvard

April 1998
Case

Cephalon, Inc.

By: Peter Tufano

In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details

Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States

Citation

Educators

Purchase

1996
Chapter

Note on New Drug Development in the United States

By: S. Thomke and A. Nimgade

Keywords: Product Development; Pharmaceutical Industry; United States

Citation

June 2023 (Revised July 2024)
Case

Biogen and the Aduhelm Melee

By: Amitabh Chandra and Lauren Gunasti

Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.

This... View Details

Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry

Citation

Educators

Purchase

June 2020
Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details

Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts

Citation

Educators

Purchase

April 2017
Supplement

Imprimis (D)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also... View Details

Keywords: Decision Choices and Conditions; Growth and Development Strategy; Pharmaceutical Industry; United States

Citation

Purchase

December 1999 (Revised January 2000)
Case

Agrochemicals at Ciba-Geigy AG (B)

By: Michael L. Tushman, Wendy Smith and Daniel Radov

Focuses on Pierre Urech's efforts to change the division structure at Ciba-Geigy to facilitate the marketing of the new product. Details the relationships Urech cultivates and the strategy he pursues as "product champion." Also describes the restructuring of the... View Details